BS_RGSMX7QD
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- age_years
- 10.795
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.517
- PROTEIN_SECRETION+0.465
- ANDROGEN_RESPONSE+0.357
- ADIPOGENESIS+0.348
- PANCREAS_BETA_CELLS+0.338
- MTORC1_SIGNALING+0.325
- BILE_ACID_METABOLISM+0.264
- UV_RESPONSE_DN+0.244
- FATTY_ACID_METABOLISM+0.211
- UNFOLDED_PROTEIN_RESPONSE+0.204
Top 10 suppressed
- G2M_CHECKPOINT-0.453
- E2F_TARGETS-0.384
- WNT_BETA_CATENIN_SIGNALING-0.246
- MITOTIC_SPINDLE-0.189
- ANGIOGENESIS-0.159
- APICAL_JUNCTION-0.142
- MYC_TARGETS_V2-0.125
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.102
- DNA_REPAIR-0.068
- UV_RESPONSE_UP-0.045
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_HV8PFRBR | pilocytic astrocytoma | — | 0.778 |
| 2 | BS_GHNJ4CYC | low-grade glioma | — | 0.777 |
| 3 | BS_N210XMKR | low-grade glioma | — | 0.776 |
| 4 | BS_2EMW8ZG3 | low-grade glioma | — | 0.757 |
| 5 | BS_SDZY6RZ3 | pilocytic astrocytoma | — | 0.754 |
| 6 | SRR8518149 | — | F | 0.748 |
| 7 | BS_Y0PCBNJV | pilocytic astrocytoma | — | 0.746 |
| 8 | SRR8518337 | — | F | 0.738 |
| 9 | BS_3Q0GTSYH | pilocytic astrocytoma | — | 0.738 |
| 10 | BS_66HQ3E4Z | pilocytic astrocytoma | — | 0.730 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.517 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.465 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.357 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.348 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.338 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.325 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.264 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.244 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.211 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.204 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.203 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.184 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.174 | Inavolisib | — uncovered |
| APOPTOSIS | 0.154 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.148 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.144 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.133 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.123 | Idelalisib | — uncovered |